{"id":"W4415390112","doi":"10.1016/j.annonc.2025.10.019","title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"Daiichi Sankyo Europe; Allergan; Genentech; Servier; Astellas Pharma; Seagen; Eisai; Jazz Pharmaceuticals; Taiho Pharmaceutical; Gilead Sciences; Relay Therapeutics; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Myriad Genetics; Les Laboratories Pierre Fabre; Nipro","keywords":"Pertuzumab; Trastuzumab; Neoadjuvant therapy; Breast cancer; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00296398,0.001396565,0.001798024,0.0003359998,0.0003465165,0.001140803,0.0006735473,0.001284004,0.005375458],"category_scores_gemma":[0.001477308,0.000562075,0.00113076,0.0004054252,0.0013401,0.0008674113,0.0005242187,0.002639643,0.001164552],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001220807,"about_ca_system_score_gemma":0.001861811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006643093,"about_ca_topic_score_gemma":0.002094992,"domain_scores_codex":[0.9990758,0.0005624028,0.00005152845,0.0001173941,0.00007200279,0.0001207994],"domain_scores_gemma":[0.9988346,0.000240733,0.0002799295,0.00008808195,0.00006309863,0.0004936242],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9642038,0.01041343,0.0009870244,0.000512598,0.0003785335,0.00003804104,0.00006400698,0.0005059302,0.003602049,0.0001428511,0.001459664,0.01769204],"study_design_scores_gemma":[0.9237497,0.07322795,0.001202535,0.00003638446,0.000131908,0.00004643757,0.00001194009,0.0001327165,0.0003728829,0.00007288786,0.001007312,0.000007314499],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817109,0.004966739,0.0005754453,0.0009251812,0.0004292903,0.006504771,0.001593123,0.0000931785,0.003201281],"genre_scores_gemma":[0.9759916,0.004040354,0.001860699,0.001545476,0.0005079751,0.00808583,0.002803324,0.00003491587,0.005129902],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005375458,"threshold_uncertainty_score":0.01798266,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08287070357006318,"score_gpt":0.4633421922553893,"score_spread":0.3804714886853261,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}